EAU 2013 - Programme Book - YouMed

Sunday, 17 March - EAU Programme
Thematic Session 5
11.00 - 12.00 Joint session with the European Society of Nuclear Medicine:
Diagnostics and therapy of bone metastases in patients with
advanced prostate cancer
Red Hall 2 - Level N1
Chairs: A. Chiti, Rozzano (IT)
M. Wirth, Dresden (DE)
11.00 – 11.30 Choline & Fluoride imaging of bone metastases in prostate cancer
W. Langsteger, Linz (AT)
11.30 – 11.45 Treatment of bone metastases
B. Djavan, Vienna
11.45 – 12.00 Alpharadin: New horizons in systemic therapy
C. Parker, London (GB)
Aims and objectives
Radium-223 is a novel alpha-pharmaceutical that has been tested in men with bone metastases from
advanced prostate cancer. Radium-223 is very similar to calcium, and so is rapidly taken up in bone, and
particularly in bone metastases. It emits very high-energy alpha particles that cause lethal damage to
adjacent tumour cells.
The ALSYMPCA trial was a Phase III, randomised, double-blind, placebo-controlled study of radium-223 plus
best standard care compared with placebo plus best standard care in 921 patients with castrate resistant
prostate cancer (CRPC) and bone metastases. Radium-223 was associated with an overall survival benefit,
a delay in time to first skeletal-related event, an improvement in quality of life and a favourable safety
profile.
These results suggest that radium-223 may provide a new standard of care for the treatment of men with
CRPC and bone metastases.
EAU Milan 2013
167
Sunday